OVERVIEW

Current Treatment Strategies 2022 is organized by University Learning Systems (ULS) and will be held from Dec 07 - 09, 2022 at Westgate Las Vegas Resort & Casino, Las Vegas, Nevada, United States of America.

Description:
Our Live Pharmacology CME is perfect for medical professionals seeking to learn the latest in drug therapy. Join nurse practitioners, family physicians, physician assistants and pharmacists who have been benefiting from our exceptional pharmacology CME for over 30 years. You will enjoy our small class sizes which encourage back and forth discussion with clinical faculty from medical & pharmacy schools who see patients daily.

This conference provides 15 contact hours of pharmacy CE and (1.5 CEU) of live AAFP/ AMA PRA Category 1 Credit™, ACPE and pharmacology CE/ CME credit over three days.

Prefer not to travel or sit in the meeting space? Join us via live stream webcast & earn live CE/CME!
Miss the meeting? You can usually watch online CME courses that were recorded at the live event.

Polypharmacy in the Elderly, Overview of Drug Interactions and Internal Medicine Jeopardy
At the conclusion of this program, the participant will be able to:
Polypharmacy in the Elderly: Pitfalls, Pearls, and Plan:
1. Recognize factors leading to polypharmacy in the elderly.
2. Define inappropriate medications for elderly patients.
3. Describe tools to screen patients for polypharmacy.
4. Delineate best practices in polypharmacy through patient cases.

Overview of Drug Interactions:
5. Identify common drug interaction mechanisms including cytochrome P450 enzymes.
6. Identify ten relevant clinical drug interactions for common medications.
7. Delineate assessment and management strategies for each drug interaction.

Internal Medicine Jeopardy:
8. Identify evidence-based guideline-directed pharmacotherapy for select disease states.
9. Identify key therapeutic laboratory indices for selecting pharmacotherapy.

GI Topics: Peptic Ulcer Disease and Helicobacter Highlights, Inflammatory Bowel Disease: Probiotics, C difficile Update., Bootcamp for Elevated Liver Function Tests and Drug-Induced Liver Injury
At the conclusion of this program, the participant will be able to:

Peptic Ulcer Disease and Helicobacter Highlights
• Identify the importance of risk factors in the development of UGI bleeding. 2. Select the appropriate candidates for long-term PPI therapy. 3. Review the non-invasive ways of making an H pylori diagnosis. 4. Manage antibiotic therapy for Helicobacter 2022

Inflammatory Bowel Disease: What You Need to Know
• Distinguish Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS). 6. Describe the workup of IBD. 7. Describe the various treatments for IBD. 8. Discuss the controversies surrounding IBD.

Probiotics: Fulfilling the Promise? And C difficile Update.
• Describe the proven GI uses of probiotics. 10. Recognize the difficulty in comparing strains, studies and results. 11. Define how to best diagnose and treat Cl difficile. 12. Recognize how faecal transplants may be the ultimate probiotic. 13. Identify future uses of probiotics.

Bootcamp for Elevated Liver Function Tests
• Define Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH). 15. Recognize frequently encountered gallbladder and common duct dilemmas. 16. Identify the changing paradigm in Hemochromatosis evaluation. 17. Describe what a primary care provider should know about Hepatitis C.

Drug-Induced Liver Injury
• Describe the various subtypes of DILI 19. Describe the differential diagnosis of DILI. 20. Examine the risk factors for DILI deterioration. 21. Examine when a liver biopsy may help make the diagnosis

Opioids and Alternatives- Strategies to Optimize Success”
At the conclusion of this program, the participant will be able to:
1. Describe how the role of the use of opioids in acute, chronic, cancer/palliative care and end-of-life pain has changed in the past decade.
2. Describe the key features of 2022 Proposed CMS Recommendations/Guidelines for prescribing opioids for outpatients.
3. Differentiate addiction, physical dependency, and tolerance.
4. State key principles for managing patients with ongoing therapy that includes opioid analgesics, including stating “red flags” for opioid misuse, abuse and diversion, and how to anticipate and manage adverse drug events.
5. Identify the main characteristics of patients who would be identified as “high risk”, “moderate risk” and “low risk” for chronic opioid use.
6. State the definition of “hyperalgesia” and how to prevent/minimize this from negatively influencing the care of patients who are receiving opioids.
7. State three reasons why opioids may not be effective for some patients with chronic pain.
8. State key educational principles that should be applied to all patients and caregivers regarding the safe use, proper storage and disposal of opioids.

9. Compare and contrast the pharmacological benefits and risks of the following non-opioid pharmacological options for managing pain: a) cannabinoids; b) NSAIDS; c) anti-convulsants; and, d) anti-depressants.